BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 2020;13:125. [PMID: 32943087 DOI: 10.1186/s13045-020-00962-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Lecat CSY, Taube JB, Wilson W, Carmichael J, Parrish C, Wallis G, Kyriakou C, Lee L, Mahmood S, Papanikolaou X, Rabin NK, Sive J, Wechalekar AD, Yong K, Cook G, Popat R. Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma. Front Oncol 2021;11:703233. [PMID: 34367987 DOI: 10.3389/fonc.2021.703233] [Reference Citation Analysis]
2 Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y. Targeting Akt in cancer for precision therapy. J Hematol Oncol 2021;14:128. [PMID: 34419139 DOI: 10.1186/s13045-021-01137-8] [Reference Citation Analysis]
3 Martino M, Canale FA, Alati C, Vincelli ID, Moscato T, Porto G, Loteta B, Naso V, Mazza M, Nicolini F, Ghelli Luserna di Rorà A, Simonetti G, Ronconi S, Ceccolini M, Musuraca G, Martinelli G, Cerchione C. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. Cancers (Basel) 2021;13:2639. [PMID: 34072068 DOI: 10.3390/cancers13112639] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Hou JZ, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol 2021;14:66. [PMID: 33879198 DOI: 10.1186/s13045-021-01077-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Trezise S, Nutt SL. The gene regulatory network controlling plasma cell function. Immunol Rev 2021;303:23-34. [PMID: 34109653 DOI: 10.1111/imr.12988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Tomaipitinca L, Russo E, Bernardini G. NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. Mol Aspects Med 2021;:100968. [PMID: 34045078 DOI: 10.1016/j.mam.2021.100968] [Reference Citation Analysis]
7 Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol 2021;14:151. [PMID: 34556161 DOI: 10.1186/s13045-021-01162-7] [Reference Citation Analysis]
8 Liu H, Pan C, Song W, Liu D, Li Z, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res 2021;9:62. [PMID: 34332618 DOI: 10.1186/s40364-021-00316-6] [Reference Citation Analysis]
9 El-Kadiry AE, Rafei M, Shammaa R. Cell Therapy: Types, Regulation, and Clinical Benefits. Front Med (Lausanne) 2021;8:756029. [PMID: 34881261 DOI: 10.3389/fmed.2021.756029] [Reference Citation Analysis]
10 Su CT, Ye JC. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. J Hematol Oncol 2021;14:115. [PMID: 34301270 DOI: 10.1186/s13045-021-01109-y] [Reference Citation Analysis]
11 Strassl I, Schreder M, Steiner N, Rudzki J, Agis H, Künz T, Müser N, Willenbacher W, Petzer A, Neumeister P, Krauth MT. The Agony of Choice-Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. Cancers (Basel) 2021;13:4701. [PMID: 34572927 DOI: 10.3390/cancers13184701] [Reference Citation Analysis]
12 Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 2021;14:75. [PMID: 33941237 DOI: 10.1186/s13045-021-01084-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Cappello E, Nieri P. From Life in the Sea to the Clinic: The Marine Drugs Approved and under Clinical Trial. Life (Basel) 2021;11:1390. [PMID: 34947921 DOI: 10.3390/life11121390] [Reference Citation Analysis]
14 Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel) 2021;14:674. [PMID: 34358100 DOI: 10.3390/ph14070674] [Reference Citation Analysis]
15 Sanchez L, Dardac A, Madduri D, Richard S, Richter J. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Ther Adv Hematol 2021;12:2040620721989585. [PMID: 33796236 DOI: 10.1177/2040620721989585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
16 Casey M, Nakamura K. The Cancer-Immunity Cycle in Multiple Myeloma. Immunotargets Ther 2021;10:247-60. [PMID: 34295843 DOI: 10.2147/ITT.S305432] [Reference Citation Analysis]
17 Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol 2021. [PMID: 34267335 DOI: 10.1038/s41423-021-00732-6] [Reference Citation Analysis]
18 Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med 2021;10:4677-96. [PMID: 34165267 DOI: 10.1002/cam4.4052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Cho SF, Xing L, Anderson KC, Tai YT. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers (Basel) 2021;13:6136. [PMID: 34885245 DOI: 10.3390/cancers13236136] [Reference Citation Analysis]
20 Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, Richard S, Richter J, Sanchez L, Chari A. Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discov 2021;2:423-33. [PMID: 34661161 DOI: 10.1158/2643-3230.BCD-21-0028] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, Chu Y, Berneman ZN, Lion E, Luo F, Anguille S. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 2020;13:164. [PMID: 33272302 DOI: 10.1186/s13045-020-01001-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
22 Yamamoto L, Amodio N, Gulla A, Anderson KC. Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol 2020;10:606368. [PMID: 33585226 DOI: 10.3389/fonc.2020.606368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Martino M, Paviglianiti A. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Expert Opin Biol Ther 2021;21:1025-34. [PMID: 33412948 DOI: 10.1080/14712598.2021.1872540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nishida H. Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review. Cancers (Basel) 2021;13:2712. [PMID: 34072645 DOI: 10.3390/cancers13112712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol 2022;18:277-89. [PMID: 34854741 DOI: 10.2217/fon-2021-1090] [Reference Citation Analysis]